chrchrchr

Meet our Physicians    
Success Stories    
CHR Update    
Press Relations    
Scientific Publications    
Newsletter    
Consent Forms    

infertility

infertility

About CHR Success Stories
 

CHR Success Stories

The following articles represent an Update on CHR activities. If you want further information on any of these articles, please email Tom Weidner.


August 2008

It is a reflection of how busy the summer of 2008 is evolving that we this year are not taking a summer break in publishing monthly UPDATEs. There is simply too much going on and here are some of the highlights:

Oldest patient ever with DHEA pregnancy

Readers of UPDATEs will recall that, a while back, we set the goal of crossing the threshold of female age 46 years in establishing pregnancies. We are now very pleased to report that not only have we, indeed, crossed this threshold, but we
have even come close to age 47. We recently discharged into obstetrical care a 46 year and 9 months old female, who spontaneously had conceived after 6 weeks of DHEA, while waiting to start an IVF cycle after the usual 2 months of DHEA supplementation. This case represents so far the oldest female with a DHEA pregnancy established at CHR and probably one of the oldest females in the world to conceive after any form of infertility treatment.

Learn more about DHEA at CHR


We are also pleased to report that others in the world are also finally starting to report on DHEA. In a so far only electronically published report from Greece in Fertility & Sterility (2008) Mamas and Mamas (doi:10.1016.j.fertnstert. 2007.11.055), the authors report on five DHEA conceptions, - a rather small number, of course, in comparison to CHR’s experience. The report was, nevertheless, quite remarkable because two of the pregnancies were achieved in women with initial baseline FSH levels above 100mIU/mL. Their report, therefore, suggests that DHEA supplementation may not only be successful in establishing pregnancies in older women with diminished ovarian reserve and younger women with premature ovarian aging (POA), but also in women with outright premature ovarian failure (POF). CHR, therefore, is in the process of initiating a clinical trial of DHEA in POF patients.

Our Toronto, Canada, based colleagues (Ryan E., et al) also will soon publish their DHEA experience, which mimics ours very closely. An abstract from their center was just accepted for the upcoming Annual ASRM Meeting in San Francisco (see below) and these data will, therefore, also appear in Fertility & Sterility.

Also, View Dr. Gleicher's appearance on The Early Show on CBS, 8/4/08 where he discusses CHR's DHEA program.

A brief report from ESHRE

CHR Medical Director, Norbert Gleicher, MD, and Andrea Weghofer, MD, Ph.D, represented CHR at this year’s Annual ESHRE Meeting in Barcelona, Spain. While the weather was very hot and humid, the meeting nevertheless attracted a
record crowd of over 7,000 participants (probably the largest attendance ever at any ESHRE or ASRM meeting). And there was a lot to do!

Dr. Gleicher had been invited to speak at two special symposia during the meeting, both held in the central convention hall in front of thousands of attendees. The first, organized by FERRING, addressed the importance of LH/hCG stimulation vs. FSH-only stimulation in IVF. The second symposium, organized by IBSA in the same venue the following day, dealt with the IVF outcome difference between the U.S. and Europe. And while both of these symposia (and especially the second)
attracted fierce debates, neither reached the decibel level of one of CHR’s oral abstract presentations.

Drs. Gleicher and Weghofer presented two oral and one poster presentations with CHR data. Even before its formal oral presentation, an abstract presented by Dr. Gleicher had become a centerpiece of attention, primarily for the British press. In this abstract Dr. Gleicher presented evidence that the widely held belief that twin pregnancies represent higher risk outcomes for infertility patients than singletons was mistaken. (A detailed manuscript has been published electronically: Gleicher N and Barad D. Twin pregnancy, contrary to consensus, is a desirable outcome in infertility. Fertil Steril doi:10.1016/j.fertnstert.20 08.02.160). Since such an allegedly higher risk profile is the principal argument for the recent widely propagated concept of single embryo transfer (s-ET), establishing the higher risk profile as incorrect pulls the rug from under proponents of wide s-ET utilization.

Read more about CHR's IVF treatment plans


Practically all U.K. papers of significance reported Dr. Gleicher’s presentation. The reason for this special attention in the U.K. was the British Embryology Authority’s decision, only a week earlier, to mandate the increased use of s-ET in attempts to
reduce national twin pregnancy rates. Obviously, not a very well thought-through policy and just another example why government regulation of medical care never works.

View samples of the media coverage in response to Dr. Gleicher's ESHRE presentation.

Government regulation of fertility care is, however, especially dangerous; Focus on Reproduction, the monthly official ESHRE magazine, in its May 2008 issue, reported that Italy’s first official evaluation of Law 40 (mandating new IVF policies for the country) found a decline in ART pregnancy rates. Dr. Gleicher and other speakers noted in the ESHRE symposium on differences in IVF outcomes between the U.S. and Europe that more intensive government interventions in Europe were one of the reasons for so much poorer pregnancy rates in Europe than in the U.S. Dr. Gleicher also noted in his presentation that such interventions very frequently overlook the infertility patient’s basic right to strive for maximal pregnancy chances.

New definitions for Infertility and Recurrent Pregnancy Loss

The Practice Committee of the ASRM recently published new definitions, which are worthwhile to comment on: The first important modification is the definition of infertility as a disease. It is further defined by failure to achieve pregnancy in 12, or
more, months of unprotected intercourse
. The most important modification may, however, lie in the recommended timing for diagnostic intervention. It now states that earlier evaluation [than after 12 months] may be justified based on medical history and physical findings and is warranted after 6 months for women over age 35.

Recurrent pregnancy loss is now also defined as a disease, but distinct from infertility. It is further defined by [only] two or more failed pregnancies and already at that point merits careful review as to whether specific evaluations may be appropriate.

Both new recommendations thus practically advance the time of
appropriate diagnostic and therapeutic interventions. It seems high time for such a formal decision! Competent physicians have followed these definitions for years.

Please contact us for more on Premature Ovarian Aging.


Annual ASRM Meeting 2008

We three months ago in the UPDATE announced a record nine abstract submissions from CHR to the upcoming Annual ASRM Meeting, which this year will take place November 10 -12 in San Francisco, CA. We are now pleased to report that an unprecedented eight, out of nine, submissions have been accepted for presentation. And this doesn’t even include a number of additional abstracts on which CHR staff collaborated, but which were submitted from collaborating institutions. For example, as already noted earlier, our Toronto colleagues (Ryan et al) also had an abstract accepted, summarizing their DHEA outcome experiences.

In collaboration with this group, one of the CHR abstracts that was accepted reports on the unusually low miscarriage rate in pregnancies, established after DHEA supplementation. CHR’s and Toronto’s combined data demonstrates an approximately 50-80% reduction in expected age-specific miscarriage rates, strongly suggesting that DHEA supplementation may reduce aneuploidy (chromosomal abnormality) rates.

CHR in the Media
The Early Show, CBS
CHR Drs. Norbert Gleicher and David Barad appeared on “The Early Show” on Aug. 4, 2008 in a series entitled Medical Miracles. Dr. Gleicher described the process that has led to CHR's groundbreadking work with DHEA. Video

Newsweek Magazine
Dr. Kutluk Oktay met with the national magazine to share the story of a cancer patient who, thanks to one of Dr. Oktay’s innovative techniques, became pregnant and had a child after undergoing cancer treatments. The story appeared in the Aug.
4 issue of Newsweek. Article

 

New CHR Publications

Having passed the mid-year point, it is once again time to list CHR publications, which so far have appeared during 2008, either electronically or in print. Interested readers of this UPDATE are welcome to order reprints of any of these articles either by e-mail (editorial@thechr.com) or by calling 312-876-1506.

(1) Gleicher N. Missed immunological opportunities in pregnancy. Expert Rev Clin Immunol 2008;4:1-3

(2) Gleicher N. Graft-versus-host disease and immunologic rejection: implications for diagnosis and treatments of pregnancy complications. Expert Rev Obstet Gynecol 2008;3:37-49

(3) Weghofer A et al. Does autoimmunity play a role in the
pathophysiology of premature ovarian aging? RBM Online
2008;16:830-4

(4) Weghofer A et al. The impact of LH-containing gonadotropins on diploidy rates in preimplantation embryos: long protocol stimulation. Hum Reprod 2008;23:499-503

(5) Gleicher N and Barad D. Arguments against elective single-embryo transfer. Expert Rev Obstet Gynecol 2008; 3:481-6

(6) Gleicher N et al. Preimplantation genetic screening: “established” and ready for prime time? Fertil Steril 2008; 89:7808

(7) Gleicher N and Barad D. Single versus twin embryo implantation: Evidence, cost-effectiveness, and patient satisfaction. Gynecol & Obstet 2008;13:77-83

(8) Gleicher N et al. A pilot study of premature ovarian senescence. I. Correlation of triple CGG repeats on the FMR1 gene to ovarian reserve parameters FSH and anti-Müllerian hormone. Fertil Steril doi:10.1016/j.fertnstert.2008.01.098

(9) Gleicher N et al. A pilot study of premature ovarian senescence: II. Different genotype and phenotype for genetic and autoimmune etiologies. Fertil Steril 2008; doi:10.1016/j.fertnstert.2008.01.099

(10) Singer T et al. Correlation of antimüllerian hormone and baseline follicle-stimulating hormone levels. Fertil Steril 2008; doi:10.1016/ j.fertnstert.2008.03.034

(11) Gleicher N and Barad D. Twin pregnancy, contrary to consensus, is a desirable outcome in infertility. Fertil Steril 2008; doi:10.1016/ j.fertnstert.2008.02.160

(12) Oktay K et al. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. Journal of Clinical Oncology 2008; doi: 10.1200/JCO.2007.14.8700

(13) Oktay K et al. Can GnRH analogues preserve gonadal function without preserving fertility? Oncologist 2008 May; 13(5):615-7

(14) Oktay K and Cil AP. Who is the best candidate for oocyte cryopreservation research? Fertil Steril 2008 Apr 26 [Epub ahead of print]

(15) Oktay K et al. Terminal kinase regulates G2/M transition through a mechanism upstream of Aurora-B. Cell Cycle 2008 Feb 15; 7(4); 533-541 [Epub ahead of print]

(16) Oktem O and Oktay K. Stem cells: a perspective on oocytes. Ann N Y Acad Sci 2008 Apr; 1127:20-6

(17) Oktem O and Oktay K. The Ovary: Anatomy and function throughout human life. Ann N Y Acad Sci 2008 Apr; 1127:1-9

(18) Oktem O and Oktay K. Preservation of menstrual function in adolescent and young females. Ann N Y Acad Sci. 2008 Jun;1135:237-243

(19) Oktay K and Sonmezer M. Gonadotropin-releasing hormone analogs in fertility preservation-lack of biological basis? Nat Clin Pract Endocrinol Metab. 2008 Jul 15. [Epub ahead of print] PMID: 18628732 [PubMed - as supplied by publisher]

(20) Oktay K and Sonmezer M. Chemotherapy and amenorrhea: risks and treatment options. Curr Opin Obstet Gynecol 20:408-415 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins 1040-872X PMID: 18574230 [PubMed - as supplied by publisher]

In addition, six manuscripts are already in press, which means that they
have been accepted for publication, but have not yet appeared, and another 10 are currently under review. In other words, we anticipate another record year for CHR publications!

 

 

- The CHR

CONTACT US
To find out more about the Center for Human Reproduction, or to learn more any of our infertility solutions, please contact us.

PREVIOUS UPDATES

We will continue posting periodic UPDATES, when there is news to report from CHR. So, continue looking for them! These are exciting times at CHR, and we thank you for your interest in our work.

Previous CHR Update 07/08

Previous CHR Update 06/08

Previous CHR Update 05/08

Previous CHR Update 04/08

Previous CHR Update 03/08

Previous CHR Update 02/08

Previous CHR Update 01/08

Previous CHR Update 12/07

Previous CHR Update 11/07

Previous CHR Update 09/07

Previous CHR Update 07/07

Previous CHR Update 06/07

Previous CHR Update 05/07

Previous CHR Update 03/07

Previous CHR Update 02/07

Previous CHR Update 01/07

Previous CHR Update 12/06

Previous CHR Update 10/06

Previous CHR Update 09/06

Previous CHR Update 08/06

Previous CHR Update 06/06

Previous CHR Update 03/06

Previous CHR Update 01/06

Previous CHR Update 11/05

Previous CHR Update 10/05

Privacy Policy | Terms of Use | Designed and maintained by BusiMed, Inc. | © 2008 CHR.

 

CHR